Breast cancer patients with overall poor health are at a greater risk of both complications during treatment and mortality from competing causes. We sought to determine the association of pre-existing comorbidities on treatment-related complications and overall survival.
We identified women ages 40–90 years old from our institutional registry with stage I–II invasive breast cancer from 2005 to 2014. Recursive partitioning was used to stratify women based on pre-existing comorbidities as low, moderate, or high risk of treatment-associated complications. Cox proportional hazards model was constructed to estimate the association of risk with overall survival.
2077 women were studied. Mean age was 60 (IQR 51–68). Over half (54%) had ≥ 1 comorbid condition, and 29% experienced at least one adverse medical event within 1 year of diagnosis. Risk categories included low (no comorbidities or hypertension), moderate (combinations of comorbidities excluding congestive heart failure), and high (congestive heart failure in isolation or in combination with other conditions). High-risk women had a lower 10-year OS compared to moderate- or low-risk women (89% vs 90% vs 96%, log-rank p < 0.001). After adjustment, being at moderate (HR 2.20, 95% CI 1.30–3.72, p = 0.003) or high risk (HR 5.07, 95% CI 1.66–15.52, p = 0.004) of adverse sequelae was associated with reduced OS compared to those at low risk of these adverse medical events.
Following breast cancer diagnosis, overall poor health was associated with a greater risk of mortality and complications within the first year of treatment, which was driven by a pre-existing diagnosis of congestive heart failure.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Greenlee RT, Murray T, Bolden S et al (2000) Cancer statistics, 2000. CA Cancer J Clin 50(1):7–33
Guralnik JM (1996) Assessing the impact of comorbidity in the older population. Ann Epidemiol 6(5):376–380
Aziz D, Gardner S, Pritchard K et al (2007) Selective application of axillary node dissection in elderly women with early breast cancer. Ann Surg Oncol 14(2):652–659. https://doi.org/10.1245/s10434-006-9092-y
Yancik R, Ries LG, Yates JW (1989) Breast cancer in aging women. A population-based study of contrasts in stage, surgery, and survival. Cancer 63(5):976–981
Yancik R, Havlik RJ, Wesley MN et al (1996) Cancer and comorbidity in older patients: a descriptive profile. Ann Epidemiol 6(5):399–412
Satariano WA (1992) Comorbidity and functional status in older women with breast cancer: implications for screening, treatment, and prognosis. J Gerontol 47:24–31
Hutchins LF, Unger JM, Crowley JJ et al (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27):2061–2067. https://doi.org/10.1056/NEJM199912303412706
Lewis JH, Kilgore ML, Goldman DP et al (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21(7):1383–1389. https://doi.org/10.1200/JCO.2003.08.010
Barthelemy P, Heitz D, Mathelin C et al (2011) Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals. Crit Rev Oncol Hematol 79(2):196–204. https://doi.org/10.1016/j.critrevonc.2010.06.005
El-Tamer MB, Ward BM, Schifftner T et al (2007) Morbidity and mortality following breast cancer surgery in women: national benchmarks for standards of care. Ann Surg 245(5):665–671. https://doi.org/10.1097/01.sla.0000245833.48399.9a
Yood MU, Wells KE, Alford SH et al (2012) Cardiovascular outcomes in women with advanced breast cancer exposed to chemotherapy. Pharmacoepidemiol Drug Saf 21(8):818–827. https://doi.org/10.1002/pds.3239
Hershman DL, Shao T (2009) Anthracycline cardiotoxicity after breast cancer treatment. Oncology (Williston Park) 23(3):227–234
Land LH, Dalton SO, Jensen MB et al (2012) Influence of comorbidity on the effect of adjuvant treatment and age in patients with early-stage breast cancer. Br J Cancer 107(11):1901–1907. https://doi.org/10.1038/bjc.2012.472
Onitilo AA, Kar P, Engel JM et al (2013) Long-term cardiac and vascular disease outcomes following adjuvant tamoxifen therapy: current understanding of impact on physiology and overall survival. Minerva Med 104(2):141–153
Harris EE (2008) Cardiac mortality and morbidity after breast cancer treatment. Cancer Control 15(2):120–129. https://doi.org/10.1177/107327480801500204
Ording AG, Garne JP, Nystrom PM et al (2013) Comorbid diseases interact with breast cancer to affect mortality in the first year after diagnosis–a Danish nationwide matched cohort study. PLoS ONE 8(10):e76013. https://doi.org/10.1371/journal.pone.0076013
Patnaik JL, Byers T, Diguiseppi C et al (2011) The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst 103(14):1101–1111. https://doi.org/10.1093/jnci/djr188
Kimmick GG, Li X, Fleming ST et al (2018) Risk of cancer death by comorbidity severity and use of adjuvant chemotherapy among women with locoregional breast cancer. J Geriatr Oncol 9(3):214–220. https://doi.org/10.1016/j.jgo.2017.11.004
Louwman WJ, Janssen-Heijnen ML, Houterman S et al (2005) Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 41(5):779–785. https://doi.org/10.1016/j.ejca.2004.12.025
Wu XC, Lund MJ, Kimmick GG et al (2012) Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol 30(2):142–150. https://doi.org/10.1200/JCO.2011.36.8399
Extermann M (2000) Measuring comorbidity in older cancer patients. Eur J Cancer 36(4):453–471
Cronin-Fenton DP, Norgaard M, Jacobsen J et al (2007) Comorbidity and survival of Danish breast cancer patients from 1995 to 2005. Br J Cancer 96(9):1462–1468. https://doi.org/10.1038/sj.bjc.6603717
Bouchardy C, Rapiti E, Blagojevic S et al (2007) Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol 25(14):1858–1869. https://doi.org/10.1200/JCO.2006.10.4208
Van Leeuwen BL, Rosenkranz KM, Feng LL et al (2011) The effect of under-treatment of breast cancer in women 80 years of age and older. Crit Rev Oncol Hematol 79(3):315–320. https://doi.org/10.1016/j.critrevonc.2010.05.010
Oncology SoS (2016) Choosing Wisely: American Board of Internal Medicine https://www.choosingwisely.org/societies/society-of-surgical-oncology/. Accessed 8 June 2019
Rosenkranz KM, Bedrosian I, Feng L et al (2006) Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center. Am J Surg 192(4):541–544. https://doi.org/10.1016/j.amjsurg.2006.06.019
Mogal HD, Clark C, Dodson R et al (2017) Outcomes after mastectomy and lumpectomy in elderly patients with early-stage breast cancer. Ann Surg Oncol 24(1):100–107. https://doi.org/10.1245/s10434-016-5582-8
Hughes KS, Schnaper LA, Bellon JR et al (2013) Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 31(19):2382–2387. https://doi.org/10.1200/JCO.2012.45.2615
Hughes KS, Schnaper LA, Berry D et al (2004) Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 351(10):971–977. https://doi.org/10.1056/NEJMoa040587
Short ME, Goetzel RZ, Pei X et al (2009) How accurate are self-reports? Analysis of self-reported health care utilization and absence when compared with administrative data. J Occup Environ Med 51(7):786–796. https://doi.org/10.1097/JOM.0b013e3181a86671
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Ong, C.T., Ren, Y., Thomas, S.M. et al. Overall health at diagnosis predicts the risk of complications within the first year after breast cancer diagnosis. Breast Cancer Res Treat 182, 439–449 (2020). https://doi.org/10.1007/s10549-020-05700-8
- Breast cancer
- Treatment complications
- Recursive partitioning